More News! 28 Oct 2019 UK Company Synthesizes Long DNA Molecules with 85% Accuracy The UK biotech Camena Bioscience has proven it can synthesize long DNA molecules with more accuracy than traditional chemical synthesis. Camena tested its technology’s ability to accurately synthesize DNA molecules… October 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2022 Ori Biotech Bags €88M Investment to Automate Cell Therapy Manufacture The UK company Ori Biotech has raised €88M ($100M) in Series B cash to ease the cell therapy manufacturing bottleneck using automation and standardized data collection. The round was 40%… January 18, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2022 Microbiome Space in Spotlight as Microbiotica Sets Funding Record Competition is heating up in the microbiome niche as UK-based Microbiotica raised €60M (£50M) in a Series B round to advance two candidates designed to treat cancer and ulcerative colitis…. March 11, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
In Depth 13 Jul 2022 The biggest European biotech investments in June 2022 Oncology and AI-guided drug discovery firms roped in the biggest biotech investments in Europe in June 2022. The leading private rounds went to companies including ImCheck Therapeutics, MiroBio and Charm… July 13, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Empyrean Neuroscience launches with $22M to target CNS disorders Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous… October 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking… November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson’s that is attracting top partners worldwide. Right on time for World Parkinson’s Day… April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2017 New British Spin-Out Wants to Replace Hormonal Menopause Treatment KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built… September 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Alchemab Therapeutics unveils Alzheimer’s candidate Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium… June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2018 Update: Liver Gene Therapy 8 Times Stronger Than Usual Update (06/12/2018): uniQure has incorporated Synpromics’ strong liver promoter into a preclinical gene therapy candidate for treating hemophilia A. Published on 08/10/2018 Synpromics and uniQure have unveiled new technology for… December 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2017 British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat… September 26, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2020 Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech… April 3, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email